Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • Sacubitril/Valsartan...

Sacubitril/Valsartan may reduce mitral regurgitation in HFrEF, eliminating need for interventions

Medha BaranwalWritten by Medha Baranwal Published On 2022-10-13T09:00:39+05:30  |  Updated On 2022-10-13T12:32:46+05:30
Sacubitril/Valsartan may reduce mitral regurgitation in HFrEF, eliminating need for interventions

USA: The severity of mitral regurgitation (MR) in patients with heart failure with reduced ejection fraction (HFrEF) could be reduced by the use of sacubitril/valsartan, says a recent study published in Circulation. The findings were presented at the Heart Failure Society of America (HFSA) 2022 annual scientific meeting by Michael Felker, professor of medicine at Duke University School...

USA: The severity of mitral regurgitation (MR) in patients with heart failure with reduced ejection fraction (HFrEF) could be reduced by the use of sacubitril/valsartan, says a recent study published in Circulation. The findings were presented at the Heart Failure Society of America (HFSA) 2022 annual scientific meeting by Michael Felker, professor of medicine at Duke University School of Medicine.

The findings from the new analysis of the PROVE-HF study suggest the futility of a mitral-valve intervention in roughly half of the treated patients and stress the importance of guideline-directed medical therapy (GDMT) optimization before treatment of mitral valve disease with either surgery or percutaneous intervention, such as transcatheter edge-to-edge repair (TEER). 

The researchers on analyzing 724 people within the trial with interpretable mitral regurgitation data found that sacubitril/valsartan use at 6 months was associated with a 45% relative reduction in the risk of 3-4+ mitral regurgitation and this was sustained out to 12 months with an observed relative reduction of 44.7%. 

The researchers conducted an exploratory open-label study with the objective to examine potential cardiac remodeling associated with the use of sacubitril/valsartan among patients with HFrEF. The original findings of the PROVE-HF trial provided evidence indicating the reductions in NT-proBNP observed with the agent; this significantly correlated with improvements in markers of cardiac function and volume at 12 months. The findings from the single-group trial enrolling 794 patients were presented at the ESC Congress 2019 and simultaneously published in JAMA. 

The current analysis included 724 individuals after excluding people without interpretable mitral regurgitation data and those with prior mitral valve procedures. 

The mean age of the cohort of patients included in the HFSA 2022 data was 65.0±12.4 years, and 1.5% were men. At baseline, 76.4% of patients were using an ACE or ARB and 46.1% had nonischemic heart failure.

As part of the trial's procedure for PROVE-HF echocardiograms were performed at baseline, 6 months, and 12 months. The interpretation of the results was done in a blinded fashion and classified on a scale of 0 (none), 1+ (trace), 2+ mild, 3+ (moderate), and 4+ (severe). 

The study led to the following findings:

· Results indicated improvement in mitral regurgitation was observed from baseline through 12 months.

· The prevalence of 3-4+ mitral regurgitation specifically reduced from 14.9% to 8.2% at 6 months, which represents a 45.0% relative reduction in prevalence.

· At 12 months, the prevalence of 3-4+ was 8.4%, which reprints a 44.7% relative reduction.

· Those who experienced a decrease in 3-4+ mitral regurgitations experienced higher reductions in NT-proBNP from baseline to 12 months (912 vs 1512 pg/mL), showed greater improvement in left ventricular remodeling (11.0% vs. 7.6%) and had significantly improved KCCQ-23 scores (82.3 vs. 72.9 compared with non-responders. 

Reference:

Januzzi JL, Omar AMS, Liu Y, Murphy S, Butler J, Felker GM, Piña IL, Ward J, Solomon S, Contreras J. Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study. Circulation. 2022 Oct 2. doi: 10.1161/CIRCULATIONAHA.122.061693. Epub ahead of print. PMID: 36183276.

Circulation mitral regurgitation heart failure with reduced ejection fraction sacubitril valsartan 
Source : Circulation
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X